Figure 1. Clinical presentation by NYHA classand correlation to median EF by echocardiography and SV by USCOM.
| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website http://www.wjon.org |
Original Article
Volume 4, Number 1, February 2013, pages 18-25
Cardiotoxicity After Anthracycline Treatment in Survivors of Adult Cancers: Monitoring by USCOM, Echocardiography and Serum Biomarkers
Figures
Table
| Median | N (n = 52) | % | ||
|---|---|---|---|---|
| * The anthracycline equivalent dose was obtained multiplying the specific cumulative dose for an index. Index for Doxorubicin, Epirubicin, Daunorubicin, Mitoxantrone are 1, 0.67, 0.83 and 4, respectively. | ||||
| Age (years) | 60.1 | |||
| Karnofsky Performance Status (%) | 90.1 | |||
| Gender | ||||
| Female | 29 | 55.80% | ||
| Male | 23 | 44.20% | ||
| Tumor Type | ||||
| Breast-Cancer | 15 | 28.80% | ||
| Hodgkin Lymphoma | 6 | 11.50% | ||
| NHL | 24 | 46.10% | ||
| Soft tissue sarcoma | 4 | 7.70% | ||
| CLL | 1 | 2.00% | ||
| AML | 2 | 3.90% | ||
| Elapsed time after anthracyclines | 59 months | 52 | 100% | |
| 25 - 36 mo | 14 | 31.8% | ||
| 37 - 60 mo. | 9 | 20.5% | ||
| 61 - 84 mo. | 9 | 20.5% | ||
| 85 - 108 mo. | 7 | 15.8% | ||
| > 108 mo. | 5 | 11.4% | ||
| NYHA Class after therapy | ||||
| 0 | 34 | 65.4% | ||
| I-II | 12 | 23.1% | ||
| II | 4 | 7.7% | ||
| II-III | 2 | 3.8% | ||
| NT-pro-BNP (pg/mL) and hs-TnT (pg/mL) after therapy | NT-pro-BNP median | hs-TnT median | ||
| NYHA class 0 | 101.9 | 6.3 | 18 | 34.6% |
| NYHA class I-II | 148.3 | 6.5 | 12 | 66.7% |
| NYHA class II | 2047.3 | 42.7 | 4 | 22.2% |
| NYHY class II-III | 1137.2 | 10.9 | 2 | 11.1% |
| Cumulative anthracycline dose * | Median ± SD | |||
| Overall (mg/m2) | 300 ± 113.27 | |||
| Doxorubicin (index 1.0) | 300 ± 81.42 | 38 | 73.1% | |
| Epirubicin (equivalent × 0.67) | 368 ± 130.28 | 11 | 21.1% | |
| Daunorubicin (equivalent × 0.83) | 300 ± 0 | 2 | 3.8% | |
| Mitoxantrone (equivalent × 4.0) | 120 ± NA | 1 | 1.9% | |